Saudi Central Bank Has $1.83 Million Position in Illumina, Inc. $ILMN

Saudi Central Bank lifted its holdings in shares of Illumina, Inc. (NASDAQ:ILMN) by 85.0% during the 2nd quarter, Holdings Channel.com reports. The firm owned 10,435 shares of the life sciences company’s stock after purchasing an additional 4,795 shares during the period. Saudi Central Bank’s holdings in Illumina were worth $1,835,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently made changes to their positions in the business. BlackRock Inc. bought a new position in shares of Illumina in the second quarter valued at about $3,374,423,000. Primecap Management Co. CA bought a new stake in Illumina during the 2nd quarter worth about $617,981,000. Jupiter Topco LLC acquired a new stake in Illumina in the 2nd quarter valued at about $358,652,000. WCM Investment Management LLC increased its position in Illumina by 45.5% in the 1st quarter. WCM Investment Management LLC now owns 5,923,173 shares of the life sciences company’s stock valued at $715,579,000 after acquiring an additional 1,851,848 shares in the last quarter. Finally, Bank of New York Mellon Corp bought a new position in shares of Illumina in the second quarter worth about $293,846,000. 89.42% of the stock is currently owned by institutional investors and hedge funds.

Illumina News Roundup

Here are the key news stories impacting Illumina this week:

• Positive Sentiment: S&P 500 inclusion should support demand. Illumina will join the S&P 500 before the market opens on September 21, moving up from the S&P MidCap 400. The change is expected to generate buying from index-tracking funds and increase the company’s visibility among institutional investors. Illumina and Everpure to Join S&P 500 in September Rebalancing
• Positive Sentiment: Analyst sentiment has improved. Zacks upgraded Illumina to Rank #2, or “Buy,” citing greater optimism about its earnings outlook. The upgrade could provide additional short-term momentum. Illumina Upgraded to Buy
• Positive Sentiment: Business quality remains a bullish theme. Commentary highlights Illumina’s leadership in gene sequencing and the expanding use of genomics in diagnostics and precision medicine. Investors are weighing whether continued operational strength can justify the stock’s recent advance. ILMN Stock Keeps Climbing

Illumina Price Performance

Illumina stock opened at $211.06 on Wednesday. The firm has a market capitalization of $31.87 billion, a P/E ratio of 39.38, a PEG ratio of 3.09 and a beta of 1.46. Illumina, Inc. has a 1 year low of $88.00 and a 1 year high of $231.81. The business has a 50-day moving average of $199.86 and a 200-day moving average of $160.68. The company has a current ratio of 1.80, a quick ratio of 1.40 and a debt-to-equity ratio of 0.53.

Illumina (NASDAQ:ILMN) last announced its quarterly earnings results on Thursday, July 30th. The life sciences company reported $1.31 EPS for the quarter, beating analysts’ consensus estimates of $1.23 by $0.08. Illumina had a return on equity of 29.84% and a net margin of 18.36%.The company had revenue of $1.16 billion during the quarter, compared to analysts’ expectations of $1.13 billion. During the same period in the prior year, the business posted $1.19 EPS. Illumina’s revenue was up 9.4% on a year-over-year basis. Illumina has set its FY 2026 guidance at 5.300-5.400 EPS. On average, equities analysts anticipate that Illumina, Inc. will post 5.36 EPS for the current year.

Analyst Upgrades and Downgrades

ILMN has been the topic of several research analyst reports. Deutsche Bank Aktiengesellschaft cut shares of Illumina to a “hold” rating in a research note on Wednesday, August 5th. Wall Street Zen upgraded Illumina from a “hold” rating to a “buy” rating in a research report on Saturday, August 1st. Daiwa Securities Group upgraded Illumina from a “neutral” rating to an “outperform” rating and set a $155.00 target price for the company in a research report on Thursday, May 14th. Argus raised their price target on Illumina from $180.00 to $235.00 and gave the company a “buy” rating in a report on Thursday, September 3rd. Finally, Citigroup lifted their price objective on Illumina from $95.00 to $113.00 and gave the stock a “sell” rating in a research report on Monday, August 3rd. Nine research analysts have rated the stock with a Buy rating, seven have given a Hold rating and two have issued a Sell rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Hold” and an average target price of $191.31.

Insider Activity at Illumina

In other news, SVP Christensen Wedel sold 1,033 shares of the business’s stock in a transaction on Tuesday, August 18th. The shares were sold at an average price of $191.52, for a total value of $197,840.16. Following the completion of the transaction, the senior vice president owned 14,023 shares of the company’s stock, valued at $2,685,684.96. The trade was a 6.86% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Keith A. Meister sold 119,501 shares of the company’s stock in a transaction on Friday, September 4th. The shares were sold at an average price of $218.40, for a total transaction of $26,099,018.40. Following the completion of the sale, the director owned 770,350 shares of the company’s stock, valued at approximately $168,244,440. This represents a 13.43% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold 2,062,465 shares of company stock valued at $436,589,802 in the last ninety days. Insiders own 2.90% of the company’s stock.

About Illumina

Illumina, Inc (NASDAQ: ILMN) is a global life sciences company that develops, manufactures and markets integrated systems for the analysis of genetic variation and function. Headquartered in San Diego, California and founded in 1998, Illumina offers a range of sequencing and array-based technologies used by academic researchers, clinical laboratories, pharmaceutical and biotechnology companies, consumer genomics firms and agricultural researchers to enable discovery, translational research and clinical applications.

The company’s product portfolio includes next-generation sequencing (NGS) platforms and associated consumables, microarrays for genotyping and methylation analysis, library preparation kits and targeted assays.